News articles about Celyad SA (NASDAQ:CYAD) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celyad SA earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.8707058332264 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of equities analysts recently weighed in on CYAD shares. Piper Jaffray Companies reissued a “buy” rating and issued a $49.00 price target (up previously from $35.00) on shares of Celyad SA in a research note on Friday, September 1st. BidaskClub cut Celyad SA from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, ValuEngine raised Celyad SA from a “sell” rating to a “hold” rating in a research note on Thursday, June 29th.

Shares of Celyad SA (NASDAQ:CYAD) traded up 4.683% during trading on Friday, reaching $56.529. The company had a trading volume of 3,453 shares. The company has a 50 day moving average of $52.38 and a 200-day moving average of $52.38. The firm’s market capitalization is $538.44 million. Celyad SA has a 52-week low of $16.31 and a 52-week high of $57.30.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Insider Buying and Selling by Quarter for Celyad SA (NASDAQ:CYAD)

Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.